Evidence map›Paper›PMID 38871877›Full record

ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2024

Optical coherence tomography biomarkers in MYO7A-inherited retinal dystrophy: longitudinal study in pediatric patients.

Olaia Subirà, Jaume Català-Mora, Cristina Del Prado, Jesús Díaz-Cascajosa, Marina Barraso Rodrigo, Estefanía Cobos, Cinthia Aguilera, Anna Esteve-Garcia, José García-Arumí, Josep M Caminal

Abstract read
PubMed Publisher
In one paragraph

Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Olaia SubiràOphthalmology Department, Hospital Universitari de Vall d'Hebron, Passeig de la Vall d'Hebron, 119, 08035, Barcelona, Spain. olaia.subira@vallhebron.cat.ORCID http://orcid.org/0000-0003-1013-1066
Jaume Català-MoraOphthalmology Department, Hospital de Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain.
Cristina Del PradoOphthalmology Department, Hospital de Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain.
Jesús Díaz-CascajosaOphthalmology Department, Hospital de Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain.
Marina Barraso RodrigoOphthalmology Department, Hospital de Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain.
Estefanía CobosOphthalmology Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
Cinthia AguileraLaboratori Clínic Territorial Metropolitana Sud, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Clinical Genetics Unit, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain.
Anna Esteve-GarciaLaboratori Clínic Territorial Metropolitana Sud, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Clinical Genetics Unit, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain.
José García-ArumíOphthalmology Department, Hospital Universitari de Vall d'Hebron, Passeig de la Vall d'Hebron, 119, 08035, Barcelona, Spain.
Josep M CaminalOphthalmology Department, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study aims to answer a key question: is MYO7A-inherited retinal dystrophy (MYO7A-IRD) a photoreceptor-first or retinal pigment epithelium-first disease? A second aim was to determine the most useful biomarkers to monitor disease progression in pediatric patients with Usher syndrome type 1B (USH1) secondary to MYO7A mutation.

methodsFifty-two eyes from 26 patients with genetically-confirmed MYO7A-IRD underwent swept-source optical coherence tomography (SS-OCT). Structural abnormalities were evaluated and correlated with follow-up time and best corrected visual acuity (BCVA). All patients were evaluated at baseline and after ≥ 40 months of follow-up.

resultsThe mean (SD) patient age was 9.92 (± 4.1) years. Mean follow-up time was 43 (± 3.2) months. At the final evaluation, the most common qualitative abnormalities in the subfoveal area were alterations in the photoreceptor outer segments (76.9% of eyes) and in the interdigitation zone (IZ) (80.8%). The presence of cystoid macular edema at baseline was independently associated with worse BCVA at the final assessment (increase in LogMAR estimate = 0.142; t(45.00) = 2.78, p = 0.009). The mean width of the ellipsoid and interdigitation zones decreased significantly (by 668 μm and 278 μm, respectively; both p < 0.001).

conclusionThis study shows that disruption of the photoreceptor outer segments and the IZ are the first alterations detected by SS-OCT in the early phases of MYO7A-IRD. These data highlight the potential value of measuring the width of the ellipsoid and IZ to evaluate disease progression. These findings also demonstrate the utility of monitoring for the emergence of cystic lesions as biomarkers of worse visual prognosis in patients with MYO7A-IRD.

Indexed as

Disease ProgressionMutationMyosin VIIaTomography, Optical CoherenceVisual AcuityAdolescentBiomarkersChildChild, PreschoolDNAFemaleFluorescein AngiographyFollow-Up StudiesFundus OculiHumansMaleBiomarkersDNAMYO7A protein, humanMyosin VIIaMYO7A mutationsRetinitis pigmentosaRod-cone dystrophyUsher syndrome

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.